May 12, 2020 / 9:12 PM / 22 days ago

BRIEF-Catabasis Pharma Reports First Quarter Loss Per Share Of $0.50

May 12 (Reuters) - Catabasis Pharmaceuticals Inc:

* CATABASIS PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS

* Q1 LOSS PER SHARE $0.50

* CATABASIS PHARMA - TOP-LINE RESULTS EXPECTED IN Q4 FROM FULLY ENROLLED EDASALONEXENT GLOBAL PHASE 3 POLARISDMD TRIAL IN DUCHENNE MUSCULAR DYSTROPHY

* CATABASIS PHARMACEUTICALS - PHASE 3 POLARISDMD TRIAL IS INTENDED TO SUPPORT NDA FOR COMMERCIAL REGISTRATION OF EDASALONEXENT IN 2021

* EXPECTS IT HAS SUFFICIENT CASH TO FUND OPERATIONS THROUGH A POTENTIAL NDA FILING AND INTO Q3 2021

* AS OF MARCH 31, 2020, CATABASIS HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $55.1 MILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below